Open access
Oct 2026
Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma.
Importance Initial enfortumab vedotin (EV) dose selection is increasingly relevant in advanced urothelial carcinoma (UC). Reduced starting doses may be selected for some patients, but their associations with clinical outcomes and tolerability remain uncertain. Objective To evaluate the association of physician-select...
In-Ho Kim, Chang Gon Kim, Jungmin Jo et al.
· JAMA Network Open · 0 citations